Abstract
Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1082-1085 |
| Number of pages | 4 |
| Journal | Cancer Biology and Therapy |
| Volume | 5 |
| Issue number | 9 |
| State | Published - Sep 2006 |
Fingerprint
Keywords
- Bisphosphonates
- Bone
- Multiple myeloma
- Sequelae
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Bone complications in multiple myeloma. / Berenson, James R.; Rajdev, Lakshmi; Broder, Michael.
In: Cancer Biology and Therapy, Vol. 5, No. 9, 09.2006, p. 1082-1085.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone complications in multiple myeloma
AU - Berenson, James R.
AU - Rajdev, Lakshmi
AU - Broder, Michael
PY - 2006/9
Y1 - 2006/9
N2 - Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.
AB - Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.
KW - Bisphosphonates
KW - Bone
KW - Multiple myeloma
KW - Sequelae
UR - http://www.scopus.com/inward/record.url?scp=33751114397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33751114397&partnerID=8YFLogxK
M3 - Article
C2 - 16969119
AN - SCOPUS:33751114397
VL - 5
SP - 1082
EP - 1085
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
SN - 1538-4047
IS - 9
ER -